David Maloney, MD, PhD, completed his bachelor’s in chemistry at the Whitworth University, Spokane, WA, in 1977, before going on to obtain his medical degree from Stanford University, Stanford, CA, in 1985. Prof. Maloney completed his fellowship in internal medicine at Brigham and Woman’s Hospital, Boston, MA, followed by his medical oncology fellowship at Stanford University, where he stayed to complete his PhD in cancer biology, qualifying in 1991.
Prof. Maloney is currently the Medical Director of Cellular Immunotherapy at the Immunotherapy Integrated Research Center (IIRC), Fred Hutchinson Cancer Center, Seattle, WA . He is also the Leonard and Norma Klorfine Endowed Chair for Clinical Research, Fred Hutchinson Cancer Center, Seattle, WA, and Professor of Medicine in the Division of Oncology, University of Washington, Seattle, WA.
Prof. Maloney holds membership for various professional organizations, namely the American Association for Cancer Research, the American Society of Hematology, and the American Society for Blood and Marrow Transplantation. He is also the recipient of a number of awards such as the Society for Biological Therapy Presidential Award and the Whitworth University Distinguished Alumni Award.
Speaking on novel lymphoma, leukemia, and myeloma therapeutics
Prof. Maloney is at the forefront of clinical trials to develop cellular immunotherapies for chronic lymphocytic leukemia (CLL), non-Hodgkin Lymphoma (NHL) and multiple myeloma. Prof. Maloney’s research is currently focusing on exploring the use of antibodies as targeted-pre transplant conditioning treatment and its use in maintenance after allogeneic transplantation.
Prof. Maloney is the principal investigator of various trials investigating conditioning and maintenance strategies, namely a Phase II study of fludarabine phosphate and total-body irradiation pre-transplant in CLL (NCT00060424).